证券代码：000504 证券简称：*ST生物 公告编号：2026-011 南华生物医药股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1.本次股东会未出现否决提案的情形； 2.本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议召开时间：2026年2月12日15:00 （2）网络投票时间：2026年2月12日（星期四）。其中：通过深圳证券交易 所交易系统进行网络投票的具体时间为2026年2月12日9:15-9:25，9:30－11:30， 13:00-15:00；通过互联网投票系统进行网络投票的时间为2026年2月12日 9:15-15:00。 2.会议召开的地点：长沙高新开发区岳麓西大道1698号麓谷科技创新创业园 B1栋三层会议室 3.会议召开的方式：现场表决与网络投票相结合 4.会议召集人：公司第十二届董事会 5.会议主持人：董事长杨云先生 6.会议召开的合法合规性：本次股东会会议召开符合《中华人民共和国公司 法》《中 ...

二○二六年二月 湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2026 年第一次临时股东会的 法律意见书 湖南湘军麓和律师事务所 HUNAN XIANGJUNLUHE LAW FIRM 2026 年第一次临时股东会的法律意见书 致：南华生物医药股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）和中国证券监督管理委员会发布的 《上市公司股东会规则》（以下简称"《股东会规则》"）、《深圳证券交易所 上市公司股东会网络投票实施细则》（以下简称"《网络投票实施细则》"）等 有关规定，湖南湘军麓和律师事务所（以下简称"本所"）接受南华生物医药股 份有限公司（以下简称"公司"）的聘请，指派陈琳律师、向思律师（以下简称 "本所律师"）出席并见证了公司于 2026 年 2 月 12 日（星期四）15:00 在长沙 高新开发区岳麓西大道1698号麓谷科技创新创业园B1栋三层会议室召开的公司 2026 年第一次临时股东会（以下简称"本次会议"），并依据有关法律、法规、 规范性文件的规定以及《南华生 ...

Core Viewpoint - The A-share market is experiencing a critical phase where companies are engaging in various actions to avoid delisting due to financial indicators, particularly focusing on achieving revenue above 300 million yuan or turning losses into profits, as well as correcting negative net assets [1][2]. Group 1: Financial Indicators and Delisting Risks - The new "National Nine Articles" implemented in January 2025 raised the revenue threshold for delisting from 100 million yuan to 300 million yuan, allowing companies that can exceed this revenue to avoid delisting risks [5]. - Companies like *ST Jinglun and *ST Dongjing are attempting to cross the delisting threshold through various strategies, including revenue boosts, mergers, and asset disposals [2][6]. Group 2: Company Strategies for Survival - *ST Jinglun is trying to incorporate new business lines into its main revenue streams, but faced challenges with revenue recognition for its new server business, leading to a significant reduction in reported revenue [7][8]. - *ST Dongjing reported an expected revenue increase to between 340 million and 370 million yuan, aided by new business ventures, although it still anticipates losses [9][10]. Group 3: Mergers and Acquisitions - Mergers and acquisitions are being utilized by companies like *ST Huazhong and *ST Huike to surpass financial thresholds, with *ST Huazhong projecting a turnaround in profitability due to its acquisition of a controlling stake in Zhejiang Zhuangchen [12][13]. - *ST Huike's acquisition of a 51% stake in Nanjing Yizhengtong is also noted as a strategy to meet revenue requirements, despite market skepticism regarding its financial health [13]. Group 4: Asset Restructuring and Debt Relief - Several companies are opting for asset disposals to improve their financial standings, with *ST Zhongdi successfully turning its net assets positive through significant asset restructuring [16][17]. - Companies like *ST Nanzhi and *ST Lvkang have also engaged in asset sales to achieve similar outcomes, with *ST Nanzhi transferring real estate assets to improve its equity position [17]. Group 5: Bankruptcy and Debt Waivers - Bankruptcy restructuring has emerged as a key strategy for survival, with companies like *ST Dongyi successfully completing their restructuring plans and improving their financial positions [18]. - Debt waivers from major shareholders or creditors have been reported by several companies, allowing them to quickly enhance their net asset status [18].

Core Viewpoint - The A-share market is witnessing a critical "survival race" as companies face delisting risks due to financial indicators set by the new "National Nine Articles," which include negative profit totals, net profits, and insufficient revenue [2][4]. Group 1: Companies Facing Delisting Risks - *ST Jinglun is experiencing a severe decline, with nine consecutive trading days of limit-down, and a significant drop in trading volume to less than 5 million yuan, as it faces delisting expectations [2]. - Other companies like *ST Dongjing and *ST Huarong are attempting various strategies such as asset restructuring and debt waivers to avoid delisting, focusing on key financial indicators like revenue exceeding 300 million yuan or turning net assets positive [2][4]. Group 2: Financial Performance and Strategies - The new regulations increased the revenue threshold for delisting from 100 million yuan to 300 million yuan, prompting companies to strive for this new target to avoid delisting risks [4]. - *ST Jinglun is attempting to incorporate new business lines into its main revenue stream, while *ST Dongjing is projecting a revenue increase to between 340 million and 370 million yuan, surpassing the 300 million yuan threshold [6][8]. Group 3: Specific Company Actions - *ST Jinglun's revenue forecast for 2025 is approximately 338 million yuan, but after excluding non-core business income, the adjusted revenue is only about 86.22 million yuan, indicating a failure to turn a profit [6][7]. - *ST Huarong expects to achieve a net profit of between 6.5 million and 8 million yuan for 2025, aided by a 30% increase in revenue from its subsidiary, which it acquired a larger stake in [10]. Group 4: Market Reactions and Future Outlook - The market is closely monitoring companies that have narrowly met the revenue thresholds, with concerns about the sustainability of these figures and the potential for revenue adjustments post-audit [11][12]. - Companies are increasingly resorting to mergers and acquisitions as a strategy to enhance their financial performance and meet the new revenue requirements [10][15].

证券代码：000504 证券简称：*ST 生物 公告编号：2026-010 南华生物医药股份有限公司 股票可能被终止上市的第二次风险提示公告 公司可能触及的终止上市情形： | 具体情形 | 是否适用 （对可能触及的打勾） | | --- | --- | | 经审计的利润总额、净利润、扣除非经常性损益后 | | | 的净利润三者孰低为负值，且扣除后的营业收入低 | √ | | 于 3 亿元。 | | | 经审计的期末净资产为负值。 | | 1 | 财务会计报告被出具保留意见、无法表示意见或者 | | --- | | 否定意见的审计报告。 | | 追溯重述后利润总额、净利润、扣除非经常性损益 | | 后的净利润三者孰低为负值，且扣除后的营业收入 | | 低于 3 亿元；或者追溯重述后期末净资产为负值。 | | 财务报告内部控制被出具无法表示意见或者否定意 | | 见的审计报告。 | | 未按照规定披露内部控制审计报告，因实施完成破 | | 产重整、重组上市或者重大资产重组按照有关规定 | | 无法披露的除外。 | | 未在法定期限内披露过半数董事保证真实、准确、 | | 完整的年度报告。 | 本公司及董事会全体成 ...

Core Viewpoint - Nanhua Biopharmaceutical Co., Ltd. has officially terminated its major asset restructuring plan after nearly six months of planning due to a lack of consensus among the parties involved in the transaction [1] Group 1: Company Background and Performance Challenges - The company, originally listed as Hong Kong and Macau Industry in 1992, has undergone multiple ownership changes and name changes, finally being renamed Nanhua Biopharmaceutical in 2015 to enter the biomedicine sector [2] - The company has two main businesses: biomedicine (stem cell and immune cell storage) and energy conservation and environmental protection, but its performance has been inconsistent, with revenue still heavily reliant on cell storage [2] - The company has oscillated between being under special treatment (ST) and being delisted, facing continuous losses from 2014 to 2015, leading to its first ST designation in 2016, and again facing ST status in 2019 due to two consecutive years of losses [2] Group 2: Termination of Restructuring and Financial Impact - The company announced the termination of its plan to acquire a 51% stake in Hunan Huize Biopharmaceutical Technology Co., Ltd. due to the inability to reach an agreement on the transaction terms, with the termination not expected to have a significant adverse impact on its operations or financial status [3][4] - The company committed to not planning any major asset restructuring for at least one month following the announcement [4] Group 3: Financial Forecast and Recovery - Alongside the termination announcement, the company projected its 2025 revenue to be between 385 million to 425 million yuan, a significant increase from approximately 130 million yuan in the previous year [5] - The company expects to achieve a net profit attributable to shareholders of between 28.5 million to 32.5 million yuan in 2025, marking a turnaround from a loss of 19.846 million yuan in the same period last year [6] - The recovery is primarily driven by the acquisition of Loudi Jinhong New Materials Co., Ltd., which has enhanced revenue from resource recycling businesses, rather than the terminated biopharmaceutical acquisition [6][7]

星标 ★ IPO日报 精彩文章第一时间推送 日前，南华生物医药股份有限公司（000504.SZ，*ST生物）发布公告，正式终止筹划近半年的重大资产重组事项。 公司原计划收购湖南慧泽生物医药科技有限公司（简称"慧泽生物医药"）51%的股权，以期拓展生物医药板块，但最终因交易各方未能就交易方案达成一 致而宣告终止。 2025年上半年，公司营收仍同比下滑8.40%，在此背景下，收购金弘新材成为其打破僵局、寻求生路的重要战略落子。 2025年8月12日，*ST生物披露了《关于筹划重大资产重组暨签署股权收购意向协议的提示性公告》，宣布拟收购程泽能、易木林、长沙君合致远企业管 理咨询合伙企业（有限合伙）、长沙市履方医药信息咨询合伙企业（有限合伙）合计持有的慧泽生物医药51%股权。 张力制图 业绩困境 *ST生物的前身是1992年上市的港澳实业，经历多次易主与更名，于2015年定名"南华生物"进军生物医疗领域。 公司长期主营"生物医药"（干细胞、免疫细胞储存）和"节能环保"双主业。但其业绩始终起伏不定，核心的干细胞治疗研究产业化缓慢，收入仍依赖细胞 储存业务。 回溯过去，公司已多次在"ST"和"摘帽"间徘徊：因2014年至 ...

Group 1 - The company *ST Bio announced that its 12th Board of Directors' eighth meeting was held on January 23, 2026, via telecommunication [1] - The meeting reviewed the proposal to amend the "External Guarantee Management Measures" [1] Group 2 - International gold prices have surpassed $5,000, marking a 280% increase over the past seven years [1] - Experts suggest that the future of gold prices will depend significantly on the U.S. dollar, with a focus on the international monetary system, interest rate cuts, and technological revolutions [1]

南华生物医药股份有限公司 对外投资管理制度 第一章 总 则 第一条 为加强南华生物医药股份有限公司（以下简称"公司"） 对外投资的管理，规范公司对外投资行为，提高投资效益，合理、 有效地使用资金，依照《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"） 《深圳证券交易所股票上市规则》（以下简称"《股票上市规则》"） 等国家法律法规，以及《南华生物医药股份有限公司章程》（以下 简称"《公司章程》"）等相关制度、规则，结合公司实际情况， 制订本制度。 第二条 本制度所称对外投资，是指公司为获取未来收益而将 一定数量的货币资金、股权及经评估后的实物或无形资产等作价出 资，对外进行各种形式的投资活动。 公司对外投资类型包括但不限于： （三）股票、债券、基金、委托理财、期货等衍生品的投资； （四）法律、法规、规范性文件及《公司章程》规定，公司依法 可以从事的其他投资。 1 投资事项中涉及关联交易时，按照公司《关联交易管理制度》 执行。 第三条 公司对外投资应遵循的基本原则 （一）符合国家产业政策和公司的经营宗旨； （二）有利于促进资源的系统有效配置、提升资产质量； （三 ...

南华生物医药股份有限公司 关联交易管理制度 第一章 总则 第一条 为了规范南华生物医药股份有限公司（以下简称"公 司"）的关联交易行为，保证公司与关联方之间所发生的交易符合 公平、公开、公正的原则，确保公司的关联交易行为不损害公司和 非关联股东的合法权益，根据《中华人民共和国公司法》《中华人 民共和国证券法》《深圳证券交易所股票上市规则》（以下简称 "《股票上市规则》"）《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范运作》《深圳证券交易所上市公司自 律监管指引第 7 号——交易与关联交易》等法律、法规、规范性文 件及《南华生物医药股份有限公司章程》（以下简称"《公司章 程》"）的规定，制定本制度。 第二章 关联交易和关联人界定 第二条 本制度所指关联交易，是指公司或公司控股子公司与公 司关联人之间发生的转移资源或义务的事项，包括： （一）购买资产； （二）出售资产； （三）对外投资（含委托理财、对子公司投资等）； （四）提供财务资助（含委托贷款等）； 1 （五）提供担保（含对控股子公司担保等）； （六）租入或租出资产； （七）委托或者受托管理资产和业务； （八）赠与或者受赠资产； （九） ...